Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

FDA Authorizes First Oral Antiviral for Treatment of COVID-19
FDA Authorizes First Oral Antiviral for Treatment of COVID-19
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treat...
Eight substances added to 15th Report on Carcinogens
Eight substances added to 15th Report on Carcinogens
Eight substances have been added to the Report on Carcinogens, bringing the total list to 256 substances that are known, or reasonably anticipated, to cause cancer in humans.  ...
Ketamine therapy swiftly reduces depression and suicidal thoughts
Ketamine therapy swiftly reduces depression and suicidal thoughts

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has received a positive re...
Sanofi to buy cancer immunotherapy biotech for $1B
Sanofi to buy cancer immunotherapy biotech for $1B
Sanofi will pay $1 billion to acquire privately held Amunix Pharmaceuticals and its cancer immunotherapy technology in a deal announced Tuesday by the French pharmaceutical company. ...
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, tod...
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pou...
Omicron sweeps across nation, now 73% of new US COVID cases
Omicron sweeps across nation, now 73% of new US COVID cases
Omicron has raced ahead of other variants and is now the dominant version of the coronavirus in the U.S., accounting for 73% of new infections last week, federal health officials said Monday. ...
Biogen cuts the price tag on its Alzheimer’s drug in half
Biogen cuts the price tag on its Alzheimer’s drug in half
Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. ...
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
The FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead with a regulatory filing despite a failed phase 3 trial. ...
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. ...
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU

It was given the green light by the bloc's drugs regulator, the European Medicines Agency (EMA), on Monday.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand